Naren L. Banik
Medical University of South Carolina, USA
Naren L. Banik received Ph.D. from the University of London and did his postdoctoral studies at the Institute of Neurology, London. He is currently a Professor in the Department of Neuroscience, Medical University of South Carolina and the Ralph H. Johnson Veterans Administration Hospital. He has served on NIH study sections and editorial boards of several neuroscience-related journals. His work has been supported by NIH and VA over the years. He has published over 200 papers in reputed journals and serves as Associate Scientific Director of the State of South Carolina Spinal Cord Injury Research Fund.
Spinal cord injury (SCI) is devastating and debilitating and, depending on the severity of injury, can lead to loss of neurological function, sphincter dysfunction, and paralysis. Healthy young adults are oft en aff ected, and there is no cure. The only treatment currently available is the use of methylprednisolone (MP) with limited effi cacy. Th erefore, new therapies must be developed and/ or tested to protect cells and their processes for improvement/recovery of function. We have previously shown that use of high does estrogen (17β-estradiol) provided neuroprotection and improved locomotor function in experimental SCI in rats. Since this dose of estrogen (4 mg/kg) will never be used in clinics, the effi cacy of low doses of estrogen (1-10 μg/kg) was tested in both acute and chronic animals following injury. Our findings in acute SCI indicated attenuation of astrogliosis, microgliosis, and inflammation and protection of cells, which were correlated with reduction of the expression of death genes Bax/Bcl2. Th is work was extended to chronic SCI studies (4-6 weeks) with administration of 10ug/kg estrogen given intravenously. Like the acute, analysis of tissue samples from chronic studies demonstrated reduction of infl ammation and astroglial/microglial activation, promotion of microvessel growth, protection of neurons and oligodendrocytes, and preservation of axons. Locomotor function, as assessed using the BBB scale, demonstrated improvement at 4-6 weeks post-injury. These studies suggest that estrogen, by modulating diff erent destructive pathways, has potential as an agent for treatment of individuals with SCI. Supported by grants from NIH and VA.